- Trials with a EudraCT protocol (15)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (13)
15 result(s) found for: MIMIC.
Displaying page 1 of 1.
EudraCT Number: 2006-000281-36 | Sponsor Protocol Number: HHSC/003 | Start Date*: 2007-05-11 |
Sponsor Name:Imperial College London | ||
Full Title: A Phase I/II safety and tolerability study following autologous infusion of adult haematopoietic cells to patients with acute total anterior circulation ischaemic stroke | ||
Medical condition: Acute Total Anterior Circulation Ischaemic Stroke | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-006440-55 | Sponsor Protocol Number: Amino Acid 01/2007 | Start Date*: 2007-08-27 | |||||||||||
Sponsor Name:University Childrin's Hospital | |||||||||||||
Full Title: Effect on metabolic acidosis due to hyperammonemia of high versus low intake of amino acid in VLBW infants. | |||||||||||||
Medical condition: At birth, a VLBW infant is abruptly disconnected from the ideal source of parenteral nutrition - the placenta. If the goal of post-natal nutrition in the VLBW infant is to mimic in utero nutrition.... | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002284-14 | Sponsor Protocol Number: 1528 | Start Date*: 2012-03-14 |
Sponsor Name:Schur Pharmazeutika GmbH & Co. KG | ||
Full Title: Subacute local tolerance of an ointment containing 0.5% neomycin sulfate (Myacyne Salbe) | ||
Medical condition: Sensitive skin areas under non-occlusive and occlusive conditions | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-000238-36 | Sponsor Protocol Number: IST-399 | Start Date*: 1999-10-05 | |||||||||||
Sponsor Name:The University of Edinburgh & Lothian Health Board | |||||||||||||
Full Title: Third International Stroke Trial (IST-3) of thrombolysis for acute ischaemic stroke | |||||||||||||
Medical condition: Acute ischaemic stroke refers to strokes caused by thrombosis or embolism and accounts for 85% of all strokes. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004505-16 | Sponsor Protocol Number: CONVINCE | Start Date*: 2016-08-08 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:University College Dublin | ||||||||||||||||||||||||||||||||||||||
Full Title: CONVINCE - (COlchicine for preventioN of Vascular Inflammation in Non- CardioEmbolic stroke) – a randomised clinical trial of low-dose colchicine for secondary prevention after stroke | ||||||||||||||||||||||||||||||||||||||
Medical condition: The prevention of recurrent stroke and coronary events (fatal and non- fatal) after ischaemic stroke and transient ischaemic attack (TIA) not caused by cardiac embolism or other causes unrelated to... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: IE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) DK (Completed) PT (Completed) BE (Completed) LT (Completed) NL (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001321-32 | Sponsor Protocol Number: 198809 | Start Date*: 2015-04-14 | |||||||||||
Sponsor Name:Department of Clinical Microbiology, Hvidovre Hospital | |||||||||||||
Full Title: The efficacy of pivmecillinam 3 days respectively 5 days t.i.d against community acquired uncomplicated urinary tract infections | |||||||||||||
Medical condition: Lower Uncomplicated Urinary Tract Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002277-35 | Sponsor Protocol Number: AC16093 | Start Date*: 2017-06-01 | |||||||||||||||||||||||||||||||
Sponsor Name:University of Edinburgh [...] | |||||||||||||||||||||||||||||||||
Full Title: LACunar Intervention (LACI-2) Trial-2: Assessment of safety and efficacy of cilostazol and isosorbide mononitrate to prevent recurrent lacunar stroke and progression of cerebral small vessel disease. | |||||||||||||||||||||||||||||||||
Medical condition: lacunar (small vessel) ischaemic stroke | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001767-23 | Sponsor Protocol Number: T01/09/13 | Start Date*: 2016-02-29 | |||||||||||||||||||||
Sponsor Name:Seahorse Scientific Services Ltd. | |||||||||||||||||||||||
Full Title: A Single-Dose, Single Period, Phase II Pharmacokinetic Study To Examine TDS®-Testosterone For Its Potential To Be Inadvertently Transferred By Skin Contact After Dosing In Healthy Adult Subjects | |||||||||||||||||||||||
Medical condition: Male Hypogondism | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001766-42 | Sponsor Protocol Number: D1/09/13 | Start Date*: 2016-03-09 | |||||||||||||||||||||
Sponsor Name:Seahorse Scientific Services Ltd. | |||||||||||||||||||||||
Full Title: A Multiple-Dose, Single Period, Phase II Dose Ranging Study to Examine Testagen™ TDS®-Testosterone 5% in Adult Male Subjects | |||||||||||||||||||||||
Medical condition: Male Hypogondism | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024646-30 | Sponsor Protocol Number: CCCC_CMV_protocol | Start Date*: 2011-03-22 |
Sponsor Name:University Hospitals Birmingham NHS Foundation Trust | ||
Full Title: Anti-viral prophylaxis for prevention of cytomegalovirus (CMV) reactivation in immunocompetent patients in critical care. | ||
Medical condition: reactivation of cytomegalovirus infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002747-29 | Sponsor Protocol Number: BIA-2093-213 | Start Date*: 2019-04-24 | |||||||||||
Sponsor Name:Bial - Portela & Ca, S.A. | |||||||||||||
Full Title: Prevention of epilepsy in stroke patients at high risk of developing unprovoked seizures: anti-epileptogenic effects of eslicarbazepine acetate | |||||||||||||
Medical condition: Adult patients at high-risk to develop post-stroke epilepsy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SE (Completed) GB (GB - no longer in EU/EEA) PT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001045-14 | Sponsor Protocol Number: SAF001 | Start Date*: 2013-04-22 | |||||||||||
Sponsor Name:Promethera Biosciences | |||||||||||||
Full Title: SAF 001: A long-term safety follow-up study of patients suffering from Urea Cycle disorders (UCD) or Crigler-Najjar Syndrome (CN) having received infusions of HepaStem. | |||||||||||||
Medical condition: Crigler-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucuronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The ur... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) PT (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004074-28 | Sponsor Protocol Number: UKHEP001 | Start Date*: 2012-07-20 | |||||||||||
Sponsor Name:Promethera Biosciences | |||||||||||||
Full Title: A prospective, open label, multicenter, randomized, safety and preliminary efficacy study of one cycle of Promethera HepaStem® in Urea Cycle Disorders and Crigler-Najjar Syndrome patients | |||||||||||||
Medical condition: Crigler-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucuronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The ur... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005822-23 | Sponsor Protocol Number: REK231814 | Start Date*: 2012-10-16 | |||||||||||
Sponsor Name:Haukeland University Hospital | |||||||||||||
Full Title: CONTINUOUS SUBCUTANEOUS HYDROCORTISONE INFUSION IN CONGENITAL ADRENAL HYPERPLASIA | |||||||||||||
Medical condition: Congenital adrenal hyperplasia (CAH) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000650-11 | Sponsor Protocol Number: HEP002 | Start Date*: 2014-09-15 | |||||||||||
Sponsor Name:Promethera Biosciences | |||||||||||||
Full Title: A prospective, open label, multicountry, efficacy and safety study of several infusions of HepaStem in Urea Cycle Disorders pediatric patients. | |||||||||||||
Medical condition: The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are seven disorders to be investigated: carbamoylphosphate synthetase I deficiency [CP... | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) FR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
